Posttreatment Lymphopenia Is Associated With an Increased Risk of Redeveloping Nontuberculous Lung Disease in Patients With Mycobacterium avium Complex Lung Disease.
| Autor: | Furuuchi, Koji, Fujiwara, Keiji, Uesgi, Fumiko, Shimoda, Masafumi, Seto, Shintaro, Tanaka, Yoshiaki, Yoshiyama, Takashi, Yoshimori, Kozo, Kurashima, Atsuyuki, Ohta, Ken, Morimoto, Kozo |
|---|---|
| Předmět: |
DISEASE relapse
MYCOBACTERIAL disease treatment LUNG disease treatment REFERENCE values PATIENT aftercare STATISTICS CONFIDENCE intervals LUNG diseases MULTIVARIATE analysis RETROSPECTIVE studies LYMPHOPENIA RISK assessment DESCRIPTIVE statistics MYCOBACTERIAL diseases BRONCHIECTASIS LONGITUDINAL method LYMPHOCYTE count PROPORTIONAL hazards models DISEASE risk factors DISEASE complications |
| Zdroj: | Clinical Infectious Diseases; Jul2021, Vol. 73 Issue 1, pe152-e157, 6p |
| Abstrakt: | Background Lymphopenia has been reported as a risk factor for poor prognosis in various infectious diseases, including Mycobacterium avium complex lung disease (MAC-LD), and recurrence in several infectious diseases. However, the association between lymphopenia and the risk of redeveloping nontuberculous lung disease (NTM-LD) after completed treatment for MAC-LD is unknown. Methods We performed a retrospective cohort study with 147 patients with MAC-LD who successfully completed guideline-based therapy. Lymphopenia was defined as an absolute lymphocyte count (ALC) <1000 cells/μL based on commonly accepted reference values. Results During the median follow-up period of 41.9 months after treatment completion, 59 (40.1%) patients redeveloped NTM-LD. Patients with NTM-LD redevelopment had significantly lower posttreatment ALCs (median, 1260 vs 1420 cells/μL) than those without, and the univariate Cox proportional hazard analysis identified posttreatment ALC as a predictive factor for redevelopment (hazard ratio,.94 [95% confidence interval,.89–.99] for every increase of 100 cells/μL; P =.04). In the multivariate analysis, posttreatment ALC and the extent of bronchiectasis were independently associated with NTM-LD redevelopment. The cumulative rate of NTM-LD redevelopment was significantly higher in patients with posttreatment lymphopenia than in those without (P =.008). Conclusions Posttreatment lymphopenia could predict an increased risk of NTM-LD redevelopment after completed treatment for MAC-LD. [ABSTRACT FROM AUTHOR] |
| Databáze: | Complementary Index |
| Externí odkaz: |
|